We are pleased to share that we have launched the migraine management device Nerivio® in South Africa. Nerivio® is a USFDA-approved and CE-mark certified drug-free wearable device that uses the Remote Electrical Neuromodulation (REN) mechanism for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years). Our team launched Nerivio® at the Neurological Association of South Africa (NASA) congress in Bloemfontein on 17th April. To support both patients and healthcare practitioners, we offer the Mi-Free patient programme along with the device. The Mi-Free programme aims to aid the patient's journey with Nerivio® through education, device procurement, regular follow-ups and customer care assistance. The launch in South Africa follows the successful introduction of Nerivio® by Dr. Reddy's in India and Germany.
The NASA event was attended by 80 neurologists, psychiatrists, and general practitioners from across the country. Nerivio® was launched in the presence of Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine – Dartmouth, and Vice President, New England Institute for Neurology and Headache. Dr. Tepper, one of the world's foremost experts in headache, and lead author on several studies on neuromodulation, facilitated the clinical presentation. Dr. Tepper also spoke about the role of neuromodulation in migraine management in the plenary agenda of the NASA congress. The meeting was chaired by the President of the South African Headache Society, Dr. Michael Huth.
Migraine is a global health challenge affecting millions worldwide, particularly women. Nerivio® marks a significant advancement in migraine management, offering a clinically studied, non-pharmacologic approach for both treatment and prevention.
